https://www.pharmaceutical-technology.com/data-insights/elranatamab-pfizer-multiple-myeloma-kahler-disease-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-186194&utm_campaign=recommended-articles-pi
Elranatamab is under clinical development by Pfizer and currently in Phase III for Multiple Myeloma (Kahler Disease).
multiple myelomakahler diseaseelranatamabpfizerlikelihood